Placental Alkaline Phosphatase Antibody / ALPP

Immunohistochemistry (FFPE): 0.25-0.5ug/ml for 30 min at RT

Optimal dilution of the Placental Alkaline Phosphatase antibody should be determined by the researcher.

1. No special pretreatment is required for the immunohistochemical staining of formalin-fixed tissues.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Reacts with a 70kDa membrane-bound isozyme (Regan and Nagao type) of placental Alkaline Phosphatase (PLAP) occurring in the placenta during the 3rd trimester of gestation. It is highly specific for PLAP and shows no cross-reaction with other isozymes of alkaline phosphatase. Anti-PLAP reacts with germ cell tumors and can discriminate between these and other neoplasms. Somatic neoplasms e.g. breast, gastrointestinal, prostatic, and urinary cancers may also immunoreact with antibodies to PLAP. Anti-PLAP positivity in conjunction with anti-keratin negativity favors seminoma over carcinoma. Germ cell tumors are usually anti-keratin positive, but they regularly fail to stain with anti-EMA, whereas most carcinomas stain with anti-EMA. Anti-PLAP has been useful in the diagnosis of gestational trophoblastic disease.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

Recombinant human PLAP protein was used as the immunogen for the Placental Alkaline Phosphatase antibody.

This Placental Alkaline Phosphatase antibody is available for research use only.

Cytoplasmic and cell surface

Protein G affinity chromatography

Human

P05187